DOBUTAMINE MYLAN 250MG/20ML CONCENTRATE FOR SOLUTION FOR INFUSION

Quốc gia: Síp

Ngôn ngữ: Tiếng Hy Lạp

Nguồn: Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

Thành phần hoạt chất:

DOBUTAMINE HYDROCHLORIDE

Sẵn có từ:

MYLAN S.A.S. (0000003678) 117 ALLEE DES PARCS, SAINT PRIEST, 69800

Mã ATC:

C01CA07

INN (Tên quốc tế):

DOBUTAMINE

Liều dùng:

250MG/20ML

Dạng dược phẩm:

CONCENTRATE FOR SOLUTION FOR INFUSION

Thành phần:

DOBUTAMINE HYDROCHLORIDE (0052663817) 280MG

Tuyến hành chính:

INTRAVENOUS USE

Loại thuốc theo toa:

Ειδική άδεια άρθρο 126A

Khu trị liệu:

DOBUTAMINE

Tóm tắt sản phẩm:

Νομικό καθεστώς: Με Ιατρική Συνταγή; PACK WITH 10 AMPS X 20ML (26S026301) 10 AMPOULE - Εγκεκριμένο - Με Ιατρική Συνταγή

Tờ rơi thông tin

LEAFLET
ANSM - Mis à jour le : 24/07/2017
DOBUTAMINE MYLAN 250 MG/20 ML, CONCENTRATE FOR SOLUTION FOR INFUSION
DOBUTAMINE
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor, pharmacist or
nurse.

This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.

If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
_ _
WHAT IS IN THIS LEAFLET:
1. What DOBUTAMINE MYLAN 250 mg/20 mL, concentrate for solution for
infusion is and what it
is used for
2. What do you need to know before you use DOBUTAMINE MYLAN 250 mg/20
mL, concentrate
for solution for infusion
3. How to use DOBUTAMINE MYLAN 250 mg/20 mL, concentrate for solution
for infusion
4. Possible side effects
5. How to store DOBUTAMINE MYLAN 250 mg/20 mL, concentrate for
solution for infusion
6. Further information
1.
WHAT DOBUTAMINE MYLAN 250 MG/20 ML, CONCENTRATE FOR SOLUTION FOR
INFUSION IS
AND WHAT IT IS USED FOR
A DOPAMINERGIC AND ADRENERGIC CARDIAC STIMULANT
(C01CA07: cardiovascular system)
This medicinal product is recommended for the treatment of the
following cases:
Syndromes with low cardiac output:

during or after cardiac surgical procedure;

toxic-infectious shock ;

myocardial infarction ;

serious pulmonary embolism ;

valvular heart disease and non-obstructive cardiomyopathy during
episodes of cardiac
decompensation;

change in cardiac preload associated with high levels of
end-expiratory positive pressure.
Can be used in cardiovascular functional investigation when an
exercise test is not feasible or is
insufficient.
Paediatric population
Dobutamine is indicated in all paediatric age groups (from neonates to
18 years of age) as inotropic
support in low cardiac o